Celldex Appoints Teri Lawver as Chief Commercial Officer
New Appointment: Celldex has appointed Teri Lawver as Senior Vice President and Chief Commercial Officer, succeeding Richard Wright, who is retiring after over a decade of service.
Teri Lawver's Background: Ms. Lawver brings 30 years of experience in the healthcare sector, with a strong focus on immunology and inflammation, and has held significant roles at companies like Dexcom and Johnson & Johnson.
Company's Future Plans: Lawver's expertise is expected to be crucial as Celldex prepares for the potential launch of its drug barzolvolimab and continues to advance its pipeline of therapies for allergic and inflammatory diseases.
Forward-Looking Statements: The announcement includes forward-looking statements regarding the company's future performance and the risks associated with drug development and commercialization.
Get Free Real-Time Notifications for Any Stock
Analyst Views on CLDX
About CLDX
About the author

Celldex Therapeutics' Jimenez Sells 4,166 Shares for $121,210
- Executive Trading Activity: Freddy A. Jimenez, Senior VP & General Counsel of Celldex, sold 4,166 shares on December 4, 2025, for $121,210 at a price of $29.09, reducing his direct ownership by 11.92%, indicating a cautious outlook on the company's future.
- Historical Comparison: This sale of 4,166 shares is significantly larger than Jimenez's previous sale of 771 shares on August 13, 2025, and exceeds the recent median sell size of 2,468 shares, suggesting a heightened sensitivity to market conditions.
- Company Financials: With a market capitalization of $1.82 billion, Celldex has faced deteriorating financials, reporting zero revenue in Q3 2025 and a net loss of $67 million, highlighting the severe challenges the company is currently facing.
- Other Executive Transactions: In early 2026, other executives also engaged in stock transactions, with CBO Pepin Ronald exercising options worth $105,744, reflecting differing perspectives among executives regarding the company's future despite the overall poor market performance.

Celldex Offers $25 Put Option, Attracting Investor Interest
- Put Option Appeal: The current bid for the $25.00 put option is $3.90, and if an investor sells this option, they commit to buying the stock at $25.00, effectively lowering their cost basis to $21.10, which represents a 6% discount to the current price of $26.53, making it attractive for those looking to enter at a lower price.
- Return Potential Analysis: Should the put option expire worthless, it would yield a 15.60% return on cash commitment, or 23.53% annualized, positioning this option as an appealing investment choice, especially in a volatile market environment.
- Call Option Opportunity: The $34.00 call option has a current bid of $2.00, and if an investor buys shares at $26.53 and sells this call, they could achieve a total return of 35.70% if the stock is called away at the August 2026 expiration, providing an additional revenue opportunity for investors.
- Market Volatility Consideration: The implied volatility for the put option is 76%, while for the call option it is 68%, compared to an actual trailing twelve-month volatility of 58%, indicating significant uncertainty in market expectations for Celldex's stock performance.









